65,756 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Commerzbank Aktiengesellschaft FI

Key Points

• Commerzbank Aktiengesellschaft FI acquired 65,756 Thermo Fisher Scientific shares worth approximately $33.0 million, while institutional investors and hedge funds collectively own 89.23% of the company.
• Thermo Fisher reported quarterly EPS of $6.03, beating estimates by $0.32, and revenue of $11.99 billion, up 10.5% year over year. The company reaffirmed fiscal 2026 EPS guidance of $24.93–$25.33.
• The stock opened at $590, and analysts maintain a “Moderate Buy” consensus with an average price target of $619.41. Thermo Fisher also declared a quarterly dividend of $0.47 per share, yielding approximately 0.3%.

Commerzbank Aktiengesellschaft FI purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 65,756 shares of the medical research company's stock, valued at approximately $32,967,000.

Several other hedge funds have also modified their holdings of TMO. North Dakota State Investment Board acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $7,505,000. Hudson Value Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 24.9% in the second quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company's stock valued at $8,349,000 after purchasing an additional 3,317 shares during the period. Boston Trust Walden Corp boosted its stake in shares of Thermo Fisher Scientific by 9.7% during the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company's stock worth $25,480,000 after acquiring an additional 3,873 shares in the last quarter. Xponance LLC boosted its position in Thermo Fisher Scientific by 8.1% during the fourth quarter. Xponance LLC now owns 59,295 shares of the medical research company's stock worth $34,358,000 after purchasing an additional 4,436 shares in the last quarter. Finally, Annex Advisory Services LLC grew its stake in Thermo Fisher Scientific by 12.6% in the 2nd quarter. Annex Advisory Services LLC now owns 24,656 shares of the medical research company's stock valued at $12,361,000 after acquiring an additional 2,756 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Michael D. Shafer sold 25,500 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. This trade represents a 54.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the firm's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 52,053 shares of company stock valued at $30,643,589. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Up 0.8%

NYSE:TMO opened at $590.00 on Wednesday. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $643.99. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The company has a market capitalization of $218.15 billion, a price-to-earnings ratio of 31.74, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84. The stock has a 50-day simple moving average of $533.64 and a 200 day simple moving average of $508.36.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business's revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the company posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.11%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Royal Bank Of Canada upped their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research note on Friday, July 24th. KeyCorp restated an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Piper Sandler upped their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a research note on Monday, July 27th. Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a "market perform" rating and a $520.00 target price on the stock. Finally, Wolfe Research assumed coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average target price of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source